Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 REJOICE-Ovarian05 trial of Raludotatug Deruxtecan with or without bevacizumab versus platinum doublet chemotherapy with or without bevacizumab in PARP inhibitor-progressed platinum-sensitive ovarian cancer
CTR20264011Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of raludotatug deruxtecan and bevacizumab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Merck & Co. Primary endpoints: Progression-free survival and Overall survival. Started Oct 2026; status: active.
02
Drugs
raludotatug deruxtecanbevacizumab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20264011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20264011.